ESR1 and breast cancer: However, genomic analysis showed that tamoxifen-induced endometrial tumors were not different from those in patients who did not receive tamoxifen (86), and other studies have found that patients with ER(−) PR(−) BC who are the least likely to receive tamoxifen also have a significantly increased risk of developing EC (83).